INmune Bio Inc.

The S&P 500 ended the first week of 2025 negatively, despite a strong U.S. jobs report showing 256,000 jobs added and unemployment dropping to 4.1%. This strength raises concerns over the Federal Reserve's interest rate decisions. Raymond James highlights two small-cap stocks, Black Diamond Therapeutics and INmune Bio, with significant growth potential, focusing on innovative cancer and Alzheimer's treatments, respectively.

The author discloses a long position in INMB and COYA stocks, emphasizing the article reflects personal opinions without compensation or business relationships with mentioned companies. Seeking Alpha notes past performance doesn't guarantee future results and isn't providing investment advice.

OmniScience partners with INmune Bio for a global Phase 2 Alzheimer’s trial using Vivo, a generative AI product for real-time clinical trial data analysis. The ADO2 trial investigates INmune Bio's XPro in patients with mild cognitive impairment or Alzheimer’s disease. Vivo aims to transform data into actionable insights, improving trial efficiency and data quality.

The article discusses the necessity of enabling JavaScript to run the app, as indicated by the presence of a noscript tag and empty root and portal elements.

INmune Bio, Inc. completed randomization of patients for its Phase 2 AD02 trial targeting neuroinflammation in Early AD, with 208 patients enrolled, 56% mild AD and 44% MCI. Top line cognitive results expected Q2 2025.

INmune Bio completes patient randomization in Phase 2 AD02 trial for Early Alzheimer's Disease with 208 enrolled patients, focusing on neuroinflammation biomarkers. The trial uses XPro™ to target glial cells, aiming to reduce neuroinflammation and improve brain function. Primary endpoint measures cognitive function changes after 24 weeks using EMACC and CDR-SB metrics. Top-line cognitive results expected in Q2 2025.

INmune Bio, Inc. completed randomization of patients for its Phase 2 AD02 trial on Nov. 11, focusing on Early AD and neuroinflammation. The trial, with 208 patients, aims to assess cognitive function changes after 24 weeks using XPro™, targeting glial cells to decrease neurodegeneration. Top-line results are expected in Q2 2025.

NK cell therapy, a promising cancer treatment, sees robust R&D with 140+ companies developing 160+ therapies. Key players include Amgen, Innate Pharma, Nektar Therapeutics, and others. Promising therapies like Bemarituzumab, Monalizumab, and NKTR-225 are in various clinical phases. Recent milestones include Immunitybio's CAR-NK cell therapy for NHL, Nkarta's NKX019 for AAV, and KGen Biotech's SNK01 advancing to Phase II.

INMUNE BIO INC. filed a Form 8-K report on October 31, 2024, announcing financial results and business updates for Q3 2024, furnished as Exhibit 99.1. The company is an emerging growth company listed on NASDAQ under the symbol INMB.